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PolyglutamineSpinocerebellar ataxia type 3 (SCA3/MJD) is a neurodegenerative disease triggered by the expansion of CAG re-
peats in the ATXN3 gene. Here, we report the generation of the ﬁrst humanized ataxin-3 knock-in mouse model
(Ki91), which provides insights into the neuronal and glial pathology of SCA3/MJD. First, mutant ataxin-3 accu-
mulated in cell nuclei across the Ki91 brain, showing diffused immunostaining and forming intranuclear inclu-
sions. The humanized allele revealed expansion and contraction of CAG repeats in intergenerational
transmissions. CAG mutation also exhibited age-dependent tissue-speciﬁc expansion, which was most promi-
nent in the cerebellum, pons and testes of Ki91 animals.Moreover, Ki91mice displayed neuroinﬂammatory pro-
cesses, showing astrogliosis in the cerebellar white matter and the substantia nigra that paralleled the
transcriptional deregulation of Serpina3n, a molecular sign of neurodegeneration and brain damage. Simulta-
neously, the cerebellar Purkinje cells in Ki91 mice showed neurodegeneration, a pronounced decrease in
Calbindin D-28 k immunoreactivity and a mild decrease in cell number, thereby modeling the degeneration of
the cerebellum observed in SCA3. Moreover, these molecular and cellular neuropathologies were accompanied
by late behavioral deﬁcits in motor coordination observed in rotarod and static rod tests in heterozygous Ki91
animals. In summary,we created an ataxin-3 knock-inmousemodel that combines themolecular and behavioral
disease phenotypes with the genetic features of SCA3. This model will be very useful for studying the pathogen-
esis and responses to therapy of SCA3/MJD and other polyQ disorders.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Spinocerebellar ataxia 3 (SCA3), also calledMachado-Joseph disease
(MJD), is a dominantly inherited disease resulting from the expansion of
CAG repeats in exon 10 of the ATXN3 gene (Kawaguchi et al., 1994)
(MJD & ATXN3: OMIM 109150 & 607047). Healthy individuals present
a non-pathogenic number of repeats, usually between 13 and 41 CAGs
(Giunti et al., 1995), whereas SCA3 patients typically express 60–82
CAG repeats in one allele of ATXN3. The presence of this mutant allele
evokes motor abnormalities, such as ataxia, parkinsonism, sensory
loss, spasticity and ocular symptoms, which become evident in the
third or fourth decade of life (Riess et al., 2008).
The mechanisms of pathogenesis in SCA3 and other polyglutamine
(polyQ) diseases have been thoroughly discussed (Paulson, 2012;
Switonski et al., 2012). In brief, the relevant pathogenesis of SCA3 isChemistry, Polish Academy of
lodkrzy@ibch.poznan.pl
ect.com).
. This is an open access article underbased on the toxic function of the mutant ataxin-3 protein (Riess
et al., 2008), but the exact mechanism of the disease remains elusive.
Mouse models of polyQ diseases have been very useful in exploring
the pathogenesis and therapies of this disease (for review: (Figiel
et al., 2012)). To date, 14 models and variants of SCA3 mouse models
have been created, but the majority of them express cDNA driven by
unrelated promoters, such as Purkinje-speciﬁc L7, PrP, rHTT and CMV
promoters (Bichelmeier et al., 2007; Boy et al., 2010; Boy et al., 2009;
Cemal et al., 2002; Goti et al., 2004; Ikeda et al., 1996; Silva-Fernandes
et al., 2010). In addition, a C-terminal ataxin-3 cDNA genetrap model,
without the N-terminal region of the protein and without a CAG repeat
tract, has recently demonstrated ataxia-like changes (Hübener et al.,
2011). All of these models have reproduced many features of SCA3
pathogenesis. However, the models show an unnatural expression pat-
tern, both in tissues and during development, due to the use of unrelat-
ed promoters, the lack of regulatory ﬂanking sequences or the presence
of an excessive number of transgene copies. In addition, these models
still expressmousewild-type (WT) ataxin-3, so it is difﬁcult to precisely
investigate its inﬂuence during disease. The only full gene model is the
YAC transgenic (Cemal et al., 2002), which contains regulatory se-
quences of human origin and the mouse ataxin-3 gene. To create athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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knock-in allele. Possible strategies involve the insertion of long CAG re-
peats into the Atxn3 gene or creating amodiﬁcation ofmouse Atxn3 that
leads to the full humanization of the allele's coding sequence to produce
a human ataxin-3 mutant protein.
Here, we report the successful generation of a knock-in SCA3mouse
that contains a humanized version of the mouse Atxn3 gene and ex-
presses the human ataxin-3 protein containing 91 glutamines. We re-
veal that the SCA3 Ki91 knock-in model shows molecular and cellular
features of SCA3 pathogenesis. Moreover, Ki91 mice exhibit a late
SCA3 disease onset, which manifests as deﬁcits in coordination in the
rotarod and static rod tests. These late cellular and behavioral pheno-
types are consistent with the human SCA3 condition.
Results
Structure of the targeted Atxn3 gene and the expression of Ataxin-3 in
targeted ES cells
To generate SCA3 knock-in mice, we replaced the 3′ fragment of the
mouse Atxn3 gene with the equivalent human coding sequence, which
contains a CAG expansion in exon 10 (Fig. 1A). Analysis of the human
and mouse ataxin-3 protein sequences showed that the N-terminus of
the ataxin-3 protein, which is encoded by exons 1 through 6, is virtually
identical in mice and humans (Suppl. Fig. S1). This homology indicatesFig. 1. Targetedmodiﬁcation of themouse ataxin-3 gene. (A) The targeting vector, containing th
and a fragment of the human3′UTR,was used to replace the correspondingmouse sequence. Th
used as a source for the cDNA sequence. (B) Modiﬁed ES cells showed variable lengths of the Ps
(clone 1H8). The clones were identiﬁed by Southern blot using two probes located outside the
ataxin-3 transcripts was present in an RT-PCR analysis of the 1H8 clone. (D) Modiﬁed ES cells
41 and 67 kDa, respectively, using anti-ataxin-3 and anti-polyQ antibodies. Abbreviations: restr
after AvrII and NheI ligation.that a possible strategy to obtain a humanized locus could involve ex-
changing the less homologous 14 kb of the Atxn3 genomic sequence
containing exons 7 through 11 with human cDNA containing human
exons 7 through 11 (for a description of the targeting cassette, see Ma-
terials and Methods and Fig. 1A).
Human cDNA was derived from the GM06153 line of human ﬁbro-
blasts (Coriell Cell Repository; Camden, NJ, USA) containing 69 CAG re-
peats, which expanded to 91CAG repeatswhile processing the targeting
vector. Furthermore, the modiﬁed mouse Atxn3 allele contained four
SNP variants that are present in human GM06153 ﬁbroblasts (Fig. 1A).
Homologous recombination in the Atxn3 locus changed the PstI and
EcoRV restriction fragment lengths, and targeted clones were identiﬁed
by Southern blotting (Fig. 1B). Prior to blastocyst injection, the positive
clone (1H8) was analyzed by RT-PCR and western blotting. These anal-
yses revealed the presence of both WT and mutant ataxin-3 transcripts
andWT andmutant ataxin-3 protein expression (Figs. 1C and D). More-
over, antibodies against the expanded polyglutamine stretch (1C2) de-
tected an approximately 67-kDa band corresponding to the mutant
ataxin-3 protein (Fig. 1D). The presence of this band indicates that
CAG expansion was translated into the polyglutamine domain.
Intergenerational instability of the CAG mutation in Ki91 mice
We established a colony of Ki91 animals originating from four
NEOR-free heterozygous animals. These mice were from the F2ehybridmouse/human exon7, humanexons 8–11 (alongwith 91 CAG repeats in exon10)
emodiﬁed allele contains four SNPvariants that are present inhumanﬁbroblasts andwere
tI and EcoRV restriction genomic fragments, indicating correct homologous recombination
homology arms. (C) The mutant ataxin-3 transcript with 91 CAG repeats along with WT
expressed both WT and mutant ataxin-3 proteins, which appear as immunoblot bands of
iction sites EcoRV (E), PstI (P), AvrII (A), BglI (B) andMfeI (M); A/N – sequence generated
176 P.M. Switonski et al. / Neurobiology of Disease 73 (2015) 174–188generation (F0 are chimeric mice) and exhibited 90, 91, 91 and 92 CAG
repeats localized in the humanized Atxn3 gene. Heterozygous Ki91mice
were bred with WT C57BL/6 J mice to transfer the transgene onto the
C57BL/6 J background, and the number of CAG repeats in each newborn
heterozygous animal was determined. We observed a mild intergener-
ational instability of CAG repeats that was present in bothmaternal and
paternal transmission. Upon maternal transmission, the CAG tract
showed a tendency toward contraction (Fig. 2A, left histogram). In con-
trast, upon paternal transmission, the CAG tract showed a tendency to-
ward expansion (Fig. 2A, right histogram). An example of the CAG
repeat changes that took place after the mating of a heterozygousFig. 2.Ki91mice show intergenerational and somatic instability of the CAGmutation. (A) Interg
der of the transmitting parent and the instability pattern. Offspring usually inherit unchanged o
peats in paternal transmissions. (B) An example of an electropherogram showing the expansi
animal. (C) The gender of an offspring does not inﬂuence CAG repeat instability. The mean ch
maternal transmissions was not signiﬁcantly different. (D) Western blot with the anti-ataxin
the ataxin-3 protein in the brains of the Ki91 animals. The total protein cortical lysateswere obt
was visible in the form of expanded electrophoretic peaks with highermolecular weight in 40-w
Abbreviations: Po – pons, Cb – cerebellum, Kd – kidney, Te – testis, Sp – spleen; error bars: SEmale with a C57BL/6 J female is shown in Fig. 2B. In total, 67% of the
Ki91 offspring contained a CAG number that was different than the pa-
rental CAG number (Table 1).
The gender of the transmitting parent was signiﬁcantly associated
with intergenerational CAG repeat instability. The analysis revealed a
striking difference in the percentage of contractions versus expansions
between maternal and paternal transmissions (Fisher's exact test,
p b 0.0001). When females transmitted the transgene, CAG repeats fre-
quently contracted (58% of transmissions) but rarely expanded (11% of
transmissions). Male transmissions resulted in sporadic contractions
(5% of transmissions) and frequent expansions (59% of transmissions)enerational CAG instability in Ki91 animals showed a strong correlation between the gen-
r contracted CAG repeats in maternal transmissions and unchanged or expanded CAG re-
on in the number of CAG repeats between the male transmitting parent and its offspring
ange of the CAG repeat number between female and male offspring in both paternal and
-3 antibody demonstrates that the change in the CAG repeat number affects the size of
ained from different heterozygous Ki91 animals. (E) The somatic instability of CAG repeats
eek-old animals, which appeared in addition to the peaks observed in 10-week-oldmice.
M.
Table 1
CAG repeats are unstable in Ki91 animals, and the instability pattern is dependent on the
gender of the transmitting parent.
Paternal Maternal Total
Number of transmissions 39 36 75
Changed CAG number, n 25 (64%) 25 (69%) 50 (67%)
Expansions 23 (59%) 4 (11%) 27 (36%)
Contractions 2 (5%) 21 (58%) 23 (31%)
Mean CAG number change (SD,
range)
0.87 (1.76,
−6 to +5)
−0.61 (1.73,
−3 to +5)
0.16 (1.89,−6
to +5)
Mean male offspring CAG
number change (SD, range)
1.08 (1.18, 0
to +4)
−0.53 (1.71,
−3 to +5)
0.37 (1.63,−3
to +5)
Mean female offspring CAG
number change (SD, range)
0.53 (2.45,
−6 to 5)
−0.71 (1.79,
−3 to +5)
−0.13 (2.18,
−6 to +5)
177P.M. Switonski et al. / Neurobiology of Disease 73 (2015) 174–188of the CAG repeats (Table 1). In contrast, the gender of the offspring did
not inﬂuence the CAG repeat instability (Student's t-test, p ≥ 0.3505,
Fig. 2C).
The change in CAG repeat number was reﬂected in the number of
glutamine residues in the polyQ domain, which affected the size of the
ataxin-3 protein in the brains of Ki91 mice. Mutant ataxin-3 isoforms
of slightly different sizes could be detected by western blotting using
brain lysates from different Ki91 mice (Fig. 2D).
Somatic CAG instability in Ki91 mice
The main mutant Atxn3 allele in all animals was deduced from the
CAG-repeat proﬁling using tail-tip analysis, which was performed at
4 weeks of age. The molecular size of the main allele in each animal
was later used as a reference to investigate the instability in tissues
from the same older animal. Various animals and tissues were used
for CAG-repeat proﬁling at the ages of 10 weeks and 40 weeks. WeFig. 3. Analysis of mutant and mouse ataxin-3 protein expression in the tissues of 10-week-old
pons and the cerebellum, western blot analysis revealed the presence of a mouse ataxin-3 41-k
67-kDa band corresponding to the expectedmutant ataxin-3 proteinwas present in the heteroz
domain. The blots detected with anti-ataxin-3 antibody were re-probed with an anti-polyQ ant
peripheral tissues of Ki91 animals; however, the only tissue that does not revealmutant ataxin-3
and tissue-speciﬁc isoforms of the ataxin-3 protein.observed that the CAG-repeat proﬁles of several tissues from 40-
week-old animals showed additional expanded electrophoretic peaks
with higher molecular weights than the peaks from 10-week-old ani-
mals (Fig. 2E and Suppl. Fig. S2). Signiﬁcant expansion was observed
in the pons and the striatum in the brain, the kidney and the testes.
The most striking expansion was detected in the testes of 40-week-
old males, where the highest peak was shifted several repeats from
the main allele. Furthermore, the CAG mutation was stable in the cere-
bellum, the spleen, the lung and the muscle, where the electrophoretic
patterns were similar in 10- and 40-week-old mice. In conclusion, the
CAG mutation in the humanized ataxin-3 gene exhibited age-
dependent, tissue-speciﬁc expansion.
The human mutant Ataxin-3 is expressed in brain regions, non-neuronal
tissues and isolated astrocytes
To investigate the expression of ataxin-3 protein in transgenic mice,
total protein was extracted from the brain structures that are primarily
affected in SCA3 (cerebellum, pons, cerebral cortex and striatum,
Fig. 3A) and from non-neuronal tissues (heart and skeletal muscle,
lungs, liver, spleen, kidney and testis, Fig. 3C) and resolved by 12%
SDS–PAGE. The expression levels of WT and human mutant ataxin-3
were examined by immunoblot using a polyclonal ataxin-3 antibody,
in which the immunogen was the entire human molecule. In WT ani-
mals, the immunoblot analyses revealed a speciﬁc band representing
mouse ataxin-3with an estimatedmolecularweight of 41 kDa. A similar
mouse ataxin-3 41-kDa band was detected in heterozygous Ki91 ani-
mals and was, as expected, weaker than that observed in the WT sam-
ples. In Ki91 lysates, we were also able to detect an approximately 67-
kDa band corresponding to the mutant ataxin-3 with 91 glutamines.
The observed band was a polyglutamine protein because re-probing
the blot with an anti-polyglutamine antibody also detected the expect-
ed 67-kDa immunoreactive protein band (Fig. 3B). Mutant ataxin-3wasKi91 mice. (A) In all examined brain structures, i.e., the cerebral cortex, the striatum, the
Da band that was weaker in Ki91 heterozygous (het) animals thanWTmice. An additional
ygous Ki91 samples. (B) Themutant ataxin-3 expressed in the Ki91 brain contains a polyQ
ibody, revealing a band of the samemolecular weight. (C) Mutant ataxin-3 is expressed in
is thekidney. Some tissues exhibitWT andmutant ataxin-3 protein bands (41 and67kDa)
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the pons and the striatum and in non-neuronal tissues including
the lung, testis, liver and spleen, whereas expression was hardly
detectable in the skeletal muscles and the heart. Mutant ataxin-3 was
undetectable in the kidneys of Ki91 animals. Mutant human ataxin-3
was also expressed in isolated Ki91 cortical and cerebellar astrocytes
(Fig. 5C).Fig. 4.Mutant ataxin-3 accumulates in the nuclei of cells and nuclear inclusions in the 12-mon
with anti-ataxin-3 antibody (MAB5360). The ataxin-3 staining was of moderate intensity and w
and in the nuclei. Similar staining was present throughout the cerebellum and in other brain re
intensive accumulation of the ataxin-3-positive signal (MAB5360) in the nuclei of cells in them
Ki91 brains stained with anti-polyQ antibody (MAB1574). (C) Cells in the molecular layer of K
(D) Purkinje cells showing intense polyQ-IR and aggregates. (E, F) Intranuclear inclusionswere
ent in other brain regions.Mutant ataxin-3 accumulates in the nuclei of cells throughout the brain
To investigate the cellular expression of mutant ataxin-3, parasagittal
sections of 12-month-oldmouse knock-in brains andWTbrainswere col-
lected for ﬂuorescent immunohistochemistrywith anti-ataxin-3 antibod-
ies. The sections revealed very intense staining in the knock-in mouse
brain and less intense staining in WT brain sections (Figs. 4A and B).th-old Ki91 brain. (A) The micrograph shows a molecular layer of WT cerebellum stained
as distributed evenly throughout the cell, showing some accumulation around the nuclei
gions. (B) Cells in the Ki91 cerebellum revealed strong ataxin-3-IR. Themicrograph shows
olecular layer. Similar nuclear accumulationwas present in other Ki91 brain regions. (C–F)
i91 cerebella showing the nuclear accumulation of polyQ proteins and nuclear aggregates.
present in cells of the cerebral cortex and the hippocampus. The inclusionswere also pres-
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from knock-in mice, while the staining in WT brain sections was distrib-
uted more consistently throughout the entire cell. Such accumulation of
the staining in the nuclei of cells from the knock-in animals was evident
in the cerebellum (Figs. 4A and B) and in the cerebral cortex, the hippo-
campus, the striatum, the midbrain, the thalamus, the pons and the me-
dulla (data not shown).
In addition, we used an antibody that speciﬁcally binds polyQ do-
mains to investigate whether the brain cells of Ki91 animals contained
inclusions. As observed in sections stained with the anti–ataxin-3 anti-
body, the parasagittal sections from 12-month-old Ki91 animals
showed nuclear accumulation of polyQ protein (Fig. 4C). The cerebellar
Purkinje cells of Ki91 animals also showed a characteristic staining pat-
tern in which the entire cell soma was positive when stained with the
polyQ antibody (Fig. 4D). Moreover, we identiﬁed both intranuclear
and perinuclear inclusions in various brain regions, including the cere-
bellum (Figs. 4C and D), the cerebral cortex (Fig. 4E) and the hippocam-
pus (Fig. 4F). To further investigate ataxin-3 accumulation events,
cerebellar protein samples from aging Ki91 animals (40–73 weeks)
were subjected to western blotting using anti-ataxin-3 and anti-polyQ
antibodies. The analysis revealed an age-dependent decrease in themu-
tant 67-kDa ataxin-3 band intensity and the concurrent presence of ad-
ditional high-molecular-weight (approximately 80 kDa, 115 kDa and
125 kDa) bands (Suppl. Fig. S3).
Ki91 animals exhibit early transcriptional changes in the brain, speciﬁcally
elevated Serpina3n expression
Transcriptional deregulation of genes is a characteristic hallmark of
neurodegenerative diseases. Therefore, a range of genes including
Bdnf, Slc17a6 (Vglut2), Anp32a (Lanp), Itpr1, Hspa1b (Hsp70), Syt1,
Gabbr1, Grik2, Gabrb3 and Serpina3n (EB22/4) was selected, and their
expression was measured by real-time PCR in 40-week-old Ki91 and
WT animals in the cerebral cortex and cerebellum. The selected genes
have been shown to be deregulated in other models of SCA3 and other
neurodegenerative disorders (Chou et al., 2008; Evert et al., 2003; Lin
et al., 2000). Among the selected genes,we identiﬁed transcriptional de-
regulation of Serpina3n (Suppl. Fig. S4). The mRNA and protein expres-
sion of Serpina3n was further assessed in the cerebral cortex, the pons
and the cerebellum of 10-week-old animals by real-time PCR andwest-
ern blotting, revealing a several-fold increase compared to the levelsFig. 5. Serpina3n is a molecular marker expressed at high levels in Ki91 knock-in animals. (A
Serpina3n was increased in 10-week-old Ki91 brains. Serpina3n protein level was increased 4.
t-test, p b 0.001). Genotype of each sample is indicated. (B) ThemRNA level of Serpina3n in the
PCR (Student's t-test, p b 0.001). (C) Serpina3n protein levels were also increased in cortical an
GFAP protein. GAPDH was used as a loading control. n = 3, error bars: SEM.present in the brain regions of WT animals (Figs. 5A and B). To identify
the source of this high Serpina3n overexpression, separate astrocyte
preparations were isolated from the cortex and cerebellum of newborn
knock-in and WT animals. We found that Serpina3n protein was
overexpressed in glia isolated from knock-in animals, while low levels
were present in astrocytes from WT animals (Fig. 5C). This indicates
that the induction of Serpina3n expression is an early transcriptional
event already present in newborn Ki91 animals.
Ki91 animals show increased astrogliosis in the cerebellarwhitematter and
substantia nigra of the midbrain
Increased expression of Serpina3n in the brain and astrocytes sug-
gested the existence of an inﬂammatory process and/or reactive gliosis.
To examine the possibility of reactive gliosis, we stained the parasagittal
sections of 12-month-old knock-in andWT animals with anti-GFAP an-
tibody. Strong GFAP signals were detected in many Ki91 brain regions;
however, the signal in the cerebellum and substantia nigra revealed
particular differences in intensity. In the cerebellar white matter of
knock-in animals (Figs. 6B and D), blood vessels were readily visible
as holes surrounded by intensive GFAP-IR, while such staining was not
visible in the cerebellar white matter of WT sections (Figs. 6A and C).
In the Ki91 substantia nigra, GFAP-positive astrocytes demonstrated
thicker processes and more intense staining (Fig. 6F) compared to
those inWT animals (Fig. 6E),whichmay indicate reactive gliosis. Inter-
estingly, no changes in the overall level of GFAP protein content were
detected by immunoblot analyses of whole cerebellar protein lysates
from knock-in animals (Suppl. Fig. S5). Most likely, relatively large
amounts of GFAPmaymaskmore localized changes in GFAP expression
when immunoblotting whole cerebellar lysates.
Ki91 animals show cerebellar neurodegeneration, including a loss of
Calbindin D-28 k–IR and mild loss of Purkinje cells
Increased GFAP-IR in the brain often indicates that neurons in the vi-
cinity may be affected by neurodegeneration. To examine the condition
of Purkinje cells in the cerebellum, parasagittal sections from Ki91 and
WT animals were stained using antibodies against Calbindin D-28 k.
This Purkinje cell marker is useful in studying Purkinje cell soma mor-
phology and dendritic tree structure.Moreover, its reduction is often as-
sociated with neurodegeneration in SCA3 and other polyQ diseases) The brain structures involved in SCA3 pathogenesis revealed that the protein level of
9, 2.1 and 4.2 fold in cerebral cortex, the cerebellum and the pons respectively (Student's
cerebral cortex of Ki91micewasmassively increased, as detected by real-time quantitative
d cerebellar astrocytes isolated from P1 Ki91 animals. Cell cultures expressed glia-speciﬁc
Fig. 6. The Ki91 animals show astrogliosis in cerebellar white matter and the substantia nigra. (A) WT and (B) Ki91 tile scan micrographs of entire parasagittal sections from cerebellar
hemispheres stained with an anti-GFAP antibody. The Ki91 sections revealed strong GFAP signals in the cerebellar white matter and around vessels, which appeared slightly broadened,
delineated and readily visible (white arrows). The GFAP immunoreactive signal in cerebellar white matter wasmuch less intense inWT animals. Further magniﬁcation of the (C)WT and
(D) Ki91 posterior zone of the cerebellum. Again, the GFAP signal wasmuchmore intense in Ki91 animals, indicating reactive gliosis. (E)WT and (F) Ki91 parasagittal sections through the
substantia nigra revealed increasedGFAP staining and thicker processes in Ki91 sections compared toWT sections. DAPI nuclear stainingwas omitted for clarity. Picture data: oil 20×/0.75,
Tile scan (each tile: 2048 × 2048 pixels); ﬁnal picture: approximately 11000 × 8000 pixels. A ﬁxed detector gain was used.
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et al., 2013). The cerebellar parasagittal sections through the vermis, ei-
ther close to the midline or close to the vermal-hemispheral border,
were examined. General examination of the cerebellar sections revealed
that Calbindin D-28 k–IR was much weaker in 12-month-old knock-in
animals (Fig. 7B) compared to the respectiveWT animals (Fig. 7A). Den-
sitometric assessment (see Materials and Methods) revealed that the
immunoﬂuorescence of themolecular layer and the Purkinje cell bodies
on Calbindin D-28 k-stained knock-in sections was 40% lower than in
the respective WT animals (Fig. 7B, Graph inset). The loss of Calbindin
D-28 k–IR was not uniform across the transverse zones in the Ki91 cer-
ebellum. Although all zones across the parasagittal sections showed de-
creased Calbindin D-28 k staining, in the 12-month-old Ki91 animals,
the staining in the nodular zone (lobule 10) was very weak, while the
staining of Purkinje cell bodies remained visible in the anterior zone
(Fig. 7B). The immunoreactivity of Calbindin D-28 k depends on the
presence or absence of calcium ions in the molecule (Winsky andKuźnicki, 1996). Therefore, we investigated the expression of Calbindin
D-28 k protein by immunoblotting and found thatwhole cerebellar pro-
tein extracts from WT and Ki91 animals revealed similar levels of
Calbindin D-28 k in animals across a range of ages (10–64 weeks)
(Suppl. Fig. S6). Subsequently, we examined the structures of the
Purkinje cells and the Purkinje cell layer in more detail. Higher magniﬁ-
cation also revealed a much weaker immunoﬂuorescent Calbindin D-
28 k signal, resulting in the presence of an abundant population of
Purkinje cells where primary dendritewas invisible in knock-in sections
(Figs. 8B, C and D). Moreover, the Purkinje cell bodies in the knock-in
mice were smaller and irregular compared to those in WT mice
(Fig. 8A). Examination of single confocal planes from these image stacks
also revealed that there was a relatively abundant population of
Purkinje cells where the cell nuclei did not contain the Calbindin D-
28 k signal. In addition, Purkinje cells with more than one dendrite
were readily found in knock-in sections (Figs. 8B and D), but they
were very rarely observed in WT sections.
Fig. 7. The cerebella of KI91 animals show weak Calbindin D-28 k-IR. (A) WT and (B) Ki91 tile scan micrographs of entire parasagittal cerebellar sections (vermis close to the midline)
stained with the anti-Calbindin D-28 k antibody. The micrographs (ﬁxed detector gain) revealed a clear-cut decrease in Calbindin D-28 k–IR in Ki91 cerebellar sections. The Calbindin
D-28 k–IR intensity differed across transverse zones in the Ki91 cerebellum. Cerebellar Ki91 Lobule I/II demonstrated Calbindin D-28 k–IR, while the staining was almost lost in lobule
X. Graph inset: The densitometry quantiﬁcation of the signal from the ROI, selecting the molecular layer and Purkinje cell bodies, revealed 40% lower immunoﬂuorescence in 12-
month-old Ki91 animals than in respective WT animals. DAPI nuclear staining was omitted for clarity. Picture data: oil 20×/0.75, Tile scan (each tile: 2048 × 2048 pixels).
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detail, the number of Purkinje cells in the nodular zone (lobule 10)
and the anterior region (lobule 4/5) of Ki91 and WT mice was investi-
gated. We found that the loss of Purkinje cells in both zones of the
Ki91 cerebellumwasmild (15 % loss in lobule 4/5 and 17 % loss in lobule
10, Student's t-test, p b 0.006 and b0.02 respectively, Fig. 8E). In addi-
tion, we investigated the number of Purkinje cells with weak immuno-
reactivity for Calbindin D-28 k. A subpopulation of Purkinje cells with
invisible primary dendrites showed more than 3.5 fold increase in
Ki91 cerebella compared to WT animals (Student's t-test, p b 0.001,Fig. 8F). Moreover, a subpopulation of Purkinje cells with an unstained
nuclear compartment was about two times overrepresented in lobule
4/5 of Ki91 animals compared to WT littermates (Student's t-test,
p b 0.004, Fig. 8G).
Ki91 mice demonstrate a late disease onset with motor incoordination
To assess motor deﬁcits in Ki91 mice, we used the accelerating
rotarod and parallel rod-ﬂoor assays. The rotarod test was performed
longitudinally in 15-, 30-, 45-, 60- and 90-week-old mice. Their
Fig. 8. Cerebellar Purkinje cells in Ki91 mice show neurodegeneration. (B–D) The Purkinje cells cell bodies and dendrites from Ki91 animals showed much weaker Calbindin D-28 k–IR
compared to (A) the Purkinje cells fromWTanimals. The Ki91 Purkinje cell bodieswere smaller and irregular. (B, D) Purkinje cellswithmore than one dendrite (white arrows)were read-
ily visible in Ki91 animals. DAPI nuclear stainingwas omitted for clarity. (E –G)Quantiﬁcation of Calbindin D-28 k immunoreactive Purkinje cells in Ki91 andWTmice. (E) Loss of Purkinje
cells in both nodular zone (lobule 10) and the anterior region (lobule 4/5) of the Ki91 cerebellum was mild. (F) Weakly immunoreactive subpopulation of Purkinje cells with invisible
primary dendrites and (G) a subpopulation with an unstained nuclear compartment were signiﬁcantly overrepresented in Ki91 cerebella compared to WT animals (Student's t-test,
***p b 0.01, **p b 0.01 and *p b 0.05).
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declined in both Ki91 and WT mice (Fig. 9A, main effect of time,
p b 0.0001, two-way ANOVA). There was a signiﬁcant difference be-
tween the two genotypes (main effect of genotype, p = 0.0465, two-
way ANOVA), indicating greater rotarod impairment in Ki91 compared
to WT mice, although no time point showed a signiﬁcant difference in
the Bonferroni post hoc test. Subsequently, we analyzed the rotarod
data from four consecutive trial days for every time point of the rotarod
test. We found that the difference between the two genotypes in
rotarod performance was signiﬁcant for 90-week-old mice, indicating
rotarod impairment inKi91mice at 90 weeks (Fig. 9B;main effect of ge-
notype, p= 0.004, two-wayANOVA; Bonferroni posttest, **p b 0.01 and*p b 0.05). This change in rotarod performance was not signiﬁcant for
animals at the ages of 15, 30, 45 and 60 weeks (Suppl. Fig. S6).
The parallel rod ﬂoor test was used to examine both locomotor
activity and motor incoordination. Ki91 and WT animals at the ages of
30 and 45 weeks showed no difference in the distance traveled. In
contrast, 60-week-old Ki91 animals traveled longer distances than WT
animals, although the difference was not statistically signiﬁcant
(Fig. 9C). The Ki91 and WT mice also made a similar number of foot
slips, corrected for the distance traveled (Fig. 9D; main effect of geno-
type, p = 0.9487, two-way ANOVA). Body weight was measured from
4 to 90 weeks of age, and no differences in weight gain were observed
between male Ki91 mice and their WT male littermates (Fig. 9E).
Fig. 9.Ki91mice demonstrate rotarod impairment. (A) Rotarod performance of Ki91 andWTmales tested from 15 to 90 weeks of age. Therewere signiﬁcant differences in themean time
spent on the accelerating rod between the two genotypes (genotype p b 0.05, two-way ANOVA). (B) Rotarod performance in 4 consecutive trial days of the rotarod test of 90-week-old
Ki91 andWTanimals. The difference in rotarod performancebetween the twogenotypeswas signiﬁcant, indicating rotarod impairment forKi91 animals at 90 weeks of age (p b 0.05, two-
way ANOVA; Bonferroni posttest **p b 0.01 and *p b 0.05). (C) Parallel rod ﬂoor tests at the ages of 30 and 45 weeks showed that similar distances were traveled by both Ki91 and WT
animals during the 10-min trial. Although 60-week-old Ki91 animals traveled longer distances thanWT animals, the difference was not statistically signiﬁcant. (D) The ataxic phenotype
was assessed as the number of foot slips corrected to the travelled distance. The data were assessed with two-way ANOVA for genotype and age [n= 13 (WT) and 14 (Ki91) for rotarod
assay, n = 9 (WT) and 10 (Ki91) for the parallel rod ﬂoor test; error bars: SEM]. (E) Body weight of Ki91 and WT males. There was a similar weight gain in both genotypes.
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served in 90-week-old animals in the rotarod test, we tested a cohort
of Ki91 andWTmice (mean age: 96.6 weeks) on the static rod appara-
tus. The performance of mice to orient (turn 180°) and traverse several
oval wooden rods (35 mm, 28 mm, 21 mm, 17 mm and 9 mm in diam-
eter) was investigated. The Ki91 animals showed an increased latency
to turn 180°, and this effect was statistically signiﬁcant for the 28-mm
and 21-mm rods compared to the WT animals (Fig. 10A; main effect
of genotype, p = 0.0088 and p = 0.013 for the 28-mm and 21-mm
rods, respectively, two-way ANOVA; Bonferroni posttest, *p b 0.05).
The last 9-mm rod was too narrow for the Ki91 and WT animals, and
mostly maximum penalty scores were received for this rod (data not
shown). In addition, statistical assessment using ANOVA for repeated
measures did not reveal a signiﬁcant difference between the Ki91 and
WT animals in terms of their ability to traverse the rod after turning
around (Fig. 10B).Discussion
In a previous attempt to generate the knock-in animals, we replaced
a fragment of themouse Atxn3 gene with human cDNA encoding exons
2–11. Unfortunately, splicing events led to the lack of both mutant and
endogenous ataxin-3 protein expression (Switonski et al., 2011). There-
fore, we established a new targeting strategy, replacing the non-
homologous exons 7–11 in the mouse Atxn3 locus (Suppl. Fig. S1) and
generating new SCA3 Ki91 knock-in animals.
The ﬁrst SCA3 phenotype detected while breeding the animals was
the intergenerational instability of the CAG tract; in particular, the
tract is prone to paternal expansion and maternal contraction. In
human polyQ diseases, the gender of the transmitting parent has a sig-
niﬁcant effect on the intergenerational instability of the CAG tract.
Moreover, expansion bias in paternal transmissions and contraction
bias in maternal transmissions have been observed in patients with
Fig. 10. Ki91 mice show impaired coordination in the static rods test. The experimental
paradigm included a training day (T), followed by trial days (1-3) on rodswith an increas-
ing difﬁculty level, including 35 mm, 28 mm, 21 mm, 17 mm and 9 mm rods. (A) Perfor-
mance of mice in turning 180° on the rod, asmeasured in seconds. Compared toWTmice,
Ki91 animals required signiﬁcantly more time to turn around on 28 and 21mm rods (ge-
notype p = 0.009 and p = 0.013, respectively, two-way ANOVA for trial days 1–3;
Bonferroni posttest *p b 0.05). (B) Performance in traversing the rods, asmeasured in sec-
onds. ANOVA for repeatedmeasures did not reveal signiﬁcant differences between the ge-
notypes in terms of the time needed to traverse the rods. [n = 15 (Ki91) and 8 (WT);
mean age of animals in weeks: 97 (Ki91) and 96 (WT); error bars: SEM]. Data for the 9-
mm rod are not shown because both genotypes mostly failed the test on this rod.
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et al., 1998; Koide et al., 1994). In the case of SCA3, several publications
have reported larger expansions in paternal than in maternal transmis-
sions; however, the differences are not signiﬁcant. Instead, male trans-
missions are associated with larger variations of inherited repeat
length than maternal ones (Dürr et al., 1996; Maciel et al., 1995). In
the Ki91 model, we observed a strong correlation between parental
sex and the instability pattern. When males transmitted the transgene,
expansions accounted for 92% of unstable transmissions, whereas 84%
of all unstable events in female transmissions were contractions. More-
over, there was no clear difference in the variation of the size of the
transmitted CAG length according to the parental sex (Table 1). These
mouse-human dissimilarities in transmitted repeat instability might
be explained by inter-species factors, such as different cellular and
DNA metabolism during gametogenesis or the different chromosomal
context surrounding the CAG mutation. Nonetheless, the Ki91 mouse
model is similar to human SCA3 patients because it shows intergenera-
tional CAG repeat instability, and upon the completion of this manu-
script, we were able to generate animals containing a tract as long as
104 CAGs by selectively breeding males with longer repeats.
The CAG mutation in the humanized ataxin-3 gene exhibits age-
dependent tissue-speciﬁc expansion. The pattern of somatic instability
observed in Ki91 animals is comparable to the instability observed in
SCA3 patients. Similar to the human condition, relatively high instability
was observed in the pons, striatum, liver and kidney, and the CAG tract
was stable in tissues such as the cerebral cortex, the cerebellum, themuscle, the lung and the spleen (Cancel et al., 1998; Tanaka et al.,
1996). Testicular tissue was exceptional among the tissues tested be-
cause it showed a relatively high CAG repeat instability. The expansion
of CAG repeats in the testis of 40-week-old, but not 10-week-old, mice
suggests that expansions accumulate with age in diploid mitotic germ
cells. The notion that expansions arise in diploid germ cells agrees
with the results obtained in HD patients and DM1 mice (Savouret
et al., 2003; Zhang et al., 2002). In addition, signiﬁcantly larger expan-
sions in testicular tissue point to the existence of important tissue-
speciﬁc modiﬁers of CAG stability.
Protein expression analysis with knock-in animals showed that
human ataxin-3 from the targeted allele is ubiquitous throughout neu-
ronal and non-neuronal tissues. In particular, human ataxin-3 was
expressed in all of the brain regions tested, and the level of this expres-
sionwas similar to or greater than the level of expression from the non-
targeted WT allele. In addition, we found that the lung, testis, liver and
spleen tissues contain high levels of mutant ataxin-3, while the heart
and muscle contain a relatively low level of this protein. We also exam-
ined the expression of mutant ataxin-3 in brain cells. The immunostain-
ing showed that mutant ataxin-3 accumulated in the cell nuclei of
various brain regions, and such nuclear staining was much more prom-
inent in Ki91 compared toWT animals. In addition, our knock-in model
demonstrates that the polyQ protein forms inclusions that are both
intranuclear and outside the nucleus. The inclusions were rather infre-
quent, but they showed very intensive staining that never overlapped
with other autoﬂuorescent granules, such as lipofuscin. In addition, pro-
tein lysates from aging brain tissue of Ki91 animals revealed a decreased
level ofmutant ataxin-3 protein and the presence of extra protein bands
in blots stained with anti-Atxn3 and anti-polyQ antibodies (Suppl.
Fig. S3). This ﬁnding demonstrates that the mutant protein in Ki91 ani-
mals may be subjected to an aggregation process that intensiﬁes with
age. In addition, the role of other processes that may be involved in
the formation of additional bands in aging animals, e.g., ubiquitination
or protein interaction, cannot be excluded.
Ki91 animals also revealed transcriptional changes in the brain. The
data indicated that the induction of Serpina3n expression was an early
transcriptional event that had already occurred in newborn Ki91 ani-
mals, long before the onset of behavioral indicators of disease. In astro-
cytes, a high expression of Serpina3n is sustained without a trophic
brain environment in cell culture conditions, indicating that an intrinsic
factor, such as the expression of human mutant ataxin-3, is the direct
cause of elevated Serpina3n expression. Serpina3n and SERPINA3 are
also increased in other polyQ conditions, including the SCA1 mouse
model and in Huntington's disease (HD) patients (Lin et al., 2000;
Hodges et al., 2006).
Interestingly, the SCA3 brain expresses multiple markers of inﬂam-
mation and shows amyloid depositions (Evert et al., 2003; Evert et al.,
2001). Serpina3n is expressed during the acute inﬂammatory phase
and was identiﬁed as a highly expressed molecule that marks popula-
tions of activated astroglia (Zamanian et al., 2012). In our model,
whole cerebellar protein extracts did not show increased expression
of GFAP, which is not unusual because the overall GFAP-positive signal
in Bergmann glia is relatively high. Like SCA3 patients (Scherzed et al.,
2012), the Ki91 animals demonstrated increases in GFAP-positive glia
in cerebellar white matter, indicating the local activation of astrocytes.
These increases are often concentrated around vessels, which makes
them delineated and readily visible in Ki91 but not WT animals. Such
local changes may be a sign of the degeneration of cerebellar neurons,
nerve ﬁbers and white matter. In fact, cerebellar white matter and
peduncles are degenerated in SCA3 patients, as detected by magnetic
resonance imaging (MRI) examination and histopathology of the cere-
bellum (Scherzed et al., 2012; Guimarães et al., 2013). The presence of
increased GFAP-IR is one of the hallmarks of SCA3 in humans
(Scherzed et al., 2012), and in Ki91 mice, increased GFAP-IR accom-
panies Purkinje cell degeneration in 12-month-old cerebella. First,
whole cerebellar scans revealed that the intensity of ﬂuorescence
185P.M. Switonski et al. / Neurobiology of Disease 73 (2015) 174–188resulting from Calbindin D-28 k–IR was strongly decreased in Ki91 ver-
sus WT animals. In neurodegenerative conditions, Purkinje cells often
follow a complicated gradient pattern of degeneration that is dependent
on the cerebellar zone (Apps and Hawkes, 2009; Dufﬁn et al., 2010).
Calbindin D-28 k–IR was decreased in Ki91 mice throughout the entire
parasagittal cerebellar section, but some differences across transverse
zones were observed. However, Purkinje cell bodies in the anterior
zone of the cerebellum still showed Calbindin D-28 k–IR in 12-month-
old Ki91 animals, while such staining was almost absent in the nodular
zone (lobule 10). Pronounced degeneration of the posterior part of the
cerebellum is often observed in SCA3 patients (Scherzed et al., 2012;
Eichler et al., 2011).We also found that therewas amild loss of Purkinje
cells in 12-month-old Ki91 cerebella, while the same animals revealed
several times as many cells with weak Calbindin D-28 k staining com-
pared to WT animals; this indicates that dysfunction rather than death
of Purkinje cells may contribute to SCA3 pathogenesis in Ki91 animals.
Decreased Calbindin D-28 k–IR in the presence of similar protein ex-
pression in Ki91 and WT animals (Suppl. Fig. S6) may be explained by
the fact that the conformation and the immunoreactivity of Calbindin
D-28 k and other calcium-binding proteins are dependent on the pres-
ence or absence of calcium ions in the molecule (Winsky and
Kuźnicki, 1996; Kojetin et al., 2006; Zimmermann and Schwaller,
2002). It remains to be investigated whether Ki91 animals harbor
changes in intracellular calcium homeostasis, however, such a ﬁnding
would be in agreement with the altered calcium homeostasis already
identiﬁed in SCA3 and other polyQ mouse models (Chen et al., 2008;
Panov et al., 2002). In addition to weak Calbindin D-28 k–IR, Ki91
Purkinje cells viewed at higher magniﬁcations revealed obvious neuro-
degenerative changes in morphology, including an irregular shape,
small cell bodies, invisible primary dendrites and decreased Calbindin
D-28 k–IR in cell nuclei. Purkinje cell degeneration and the loss of
Calbindin D-28 k–IR in Ki91 mice are highly relevant because the
same changes have been observed in histopathological examinations
of SCA3 cerebella, with regions almost completely devoid of Calbindin
D-28 k–IR (Scherzed et al., 2012).
Ki91 animals at 90 weeks of age showed a signiﬁcant decrease in
rotarod performance, and similar motor incoordination was conﬁrmed
in the static rod test. A comparable late-developing behavioral pheno-
type has been reported in the full-length hemizygous SCA3 YAC
model (Cemal et al., 2002; Rodríguez-Lebrón et al., 2013). In general,
the manifestation of behavioral changes is usually late in polyQ
knock-in animals (Figiel et al., 2012). Moreover, the late motor incoor-
dination phenotype in Ki91 is consistent with the human SCA3 condi-
tion, where disease onset is usually late and becomes evident in the
third or fourth decade of life. The knock-in Ki91 SCA3 mice express a
single copy of full-length (not truncated) human mutant ataxin-3
(compared to themultiple copies in random transgenicmodels). There-
fore, it is not surprising that Ki91 animals do not develop an aggressive
phenotype. While a rapid phenotype is useful for quick screening of
drugs, the slower phenotype present in Ki91 animals may be useful
for ﬁne tuning and observing long-term consequences of therapy. In ad-
dition, in the knock-in model, the expression of transgenes and
endogenes can be strictly deﬁned, resulting in a better approximation
of patient conditions compared to simple transgenic models, which
often contain two endogenousmouse copies and several transgene cop-
ies. Additionally, the genetic vicinity of the transgene is important for
the diseasemodeling, which is a clear advantage of our knock-inmodel.
Conclusions
We present an original humanized Atxn3 knock-in mouse model
that is currently themost faithful genetic and pathogenic representation
of SCA3disease. Our knock-inmodel reveals the expansion ofmutations
in the SCA3 gene, not only in offspringmice but also in somatic tissues of
the brain. In Ki91 animals, the degeneration of neurons in the cerebel-
lum is accompanied by excessive activation of glial cells in the whitematter of the cerebellum, which corresponds to the induction of
Serpina3n expression, a marker of brain damage and neuroinﬂamma-
tion. Ki91 animals further demonstrate cerebellar degeneration with a
pronounced loss of Calbindin D-28 k–IR and a mild loss of Purkinje
cells. Moreover, the late neurodegeneration observed in SCA3 patients
is in agreement with the late motor incoordination phenotype of Ki91
animals. Thus, our knock-in model will be very useful in understanding
the pathogenesis of SCA3.
Methods
Generation of SCA3 knock-in mice
The SCA3 knock-in transgenic mouse model was generated at Poly-
Gene AG (Rümlang, Switzerland). A targeting vector backbone contain-
ing the 3′ fragment of mouse intron 6, hybridmouse/human exon 7 and
the 5′ fragment of human exon 8 was generated using DNA synthesis
and cloned into the pBlueskript vector. The BglII-BglI fragment of
human ATXN3 cDNA containing the 3′ fragment of exon 8, exons 9–11
(along with 91 CAG repeats in exon 10) and a fragment of the human
3′ UTR was cloned from human ﬁbroblasts (GM06153) and subcloned
into the targeting vector. A 7-kb 5′ homology arm (AvrII-AvrII fragment
spanning a portion of intron 5, exon 6 and intron 6) and a 2-kb 3′ ho-
mology arm (BglI-MfeI fragment spanning the portion of 3′ UTR) were
generated from the murine Sv129 BAC bMQ-421 J03 clone. The FRT-
ﬂanked neomycin resistance gene was cloned into the BamHI site,
whichwas previously created at the end of intron 6 in the targeting vec-
tor backbone. This construct was electroporated into 129/Ola ES cells,
and clones displaying G418 resistance were examined for proper ho-
mologous recombination by PCR and Southern blotting. Conﬁrmed ES
clonesweremicroinjected into C57BL/6 blastocysts. Germline transmis-
sion was obtained by crossing chimeric males with C57BL/6 females.
The NEO cassette was excised by crossing heterozygous mice with Flp
deleter animals. Mice backcrossed to C57BL/6 J for four generations
were used for experiments.
Animals
Animals weremaintained under standard conditions with an 18/6-h
light/dark cycle and provided water and food ad libitum. The animals
were marked using numerical ear tags (National Band & Tag Company,
Newport, USA). The genotype and the number of CAG repeats were de-
termined by PCR using tail-tip DNA. The animals were sacriﬁced by
placing them in a 70% CO2 atmosphere. The stress level of the animals
was minimized throughout all procedures and animal handling, which
were approved and monitored by the Local Ethical Commission for An-
imal Experiments in Poznan.
Genotyping
DNAwas prepared from tail-tip biopsies using the Spin Column Ge-
nomic DNA Kit (Bio Basic Inc., Markham, Canada). Genotypes were de-
termined by performing multiplex PCR using GoTaq Flexi DNA
Polymerase (Promega, Madison, USA). The following set of four primers
was used: forward GGACCTATCAGGACAGAGTTCACATCCA and reverse
CACATTACCAAAGTGGACCCTATGCTGT, targeting the humanized region
of the Atxn3 gene, and forward TCCTCTCTAGGATGGCTTTG and reverse
TAAACGCCCCTACCTATTTG, targeting the endogenous region of the
Atxn3 gene. The PCR cycling conditions were as follows: 3 min at
94 °C, 12× (35 s at 94 °C, [45 s at 64 °C - 0.5 °C/cycle], 45 s at 72 °C),
25× (35 s at 94 °C, 30 s at 58 °C, 45 s at 72 °C) and 2 min at 72 °C.
The reaction products were separated on 1.5% agarose gels in TBE buffer
and stained with ethidium bromide.
The number of CAG repeats was determined by performing PCR
using GoTaq Flexi DNA Polymerase with the 6-FAM-labeled forward
primer GGAAGAGACGAGAAGCCTAC and reverse primer TCACCTAGAT
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manized Atxn3 gene. The cycling conditions were as follows: 5 min at
94 °C, 30× (20 s at 94 °C, 10 s at 60 °C, 30 s at 72 °C) and 7 min at
72 °C. The PCR fragments were sized using the ABI 3130xl Analyzer
and Peak Scanner 1.0 software (Life Technologies, Carlsbad, USA).
Because the presence of CAG repeats slows the electrophoretic migra-
tion of PCR fragments, a calibration curve composed of sequence-
veriﬁed fragments with 21, 69, 81, 91 and 97 CAGs was prepared and
used to assess the exact number of CAG repeats in the analyzed samples.
RNA isolation and real-time expression analysis
Tissue samples were harvested and immediately submerged in
RNAlater solution (QIAGEN, Venlo, Netherlands). The tissue samples
were homogenized in TRI REAGENT solution (MRC; Cincinnati, USA)
using a rotor-stator homogenizer, and the total RNA was isolated ac-
cording to the manufacturer's instructions. The RNA concentration
was measured with a NanoDrop spectrophotometer. A total of 500 ng
of RNA was reverse-transcribed at 42 °C for 50 min using 200 U of
Superscript II (Life Technologies) and 125 ng of random hexamer
primers (Promega) in a ﬁnal volume of 20 μl. The light cycler 480 II
(Roche) was used for real-time PCR analysis.
Immunoblotting analyses
Tissue sampleswere harvested, immediately frozen in liquid nitrogen
and homogenized in a buffer containing 60 mM TRIS-base, 2% SDS, 10%
sucrose and 2 mM PMSF using a rotor-stator homogenizer. The protein
concentration was estimated using a NanoDrop spectrophotometer,
and 20 μg of total protein was diluted in a sample buffer containing 2-
mercaptoethanol and boiled for 5 min. The proteins were separated by
SDS–polyacrylamide gel electrophoresis (5% stacking/12% resolving
gel), transferred to nitrocellulose and stained with Ponceau S solution.
The blots were blocked with 5% nonfat milk in PBS/0.05% Tween 20
and subsequently incubated for 24 h at 4 °C with the following primary
antibodies: rat anti-ataxin-3 (1:3,000; ProteinTech Chicago, IL, USA),
mouse anti-polyQ (1:3,000; Millipore, Billerica, MA, USA), mouse anti-
GAPDH (1:20,000; Millipore), mouse anti-GFAP (1:3,000; BD
Pharmingen, Warsaw, Poland) and goat anti-Serpina3n (1:3,000, R&D
Systems,Minneapolis,MN, USA). The blotswere probedwith the respec-
tive HRP-conjugated secondary antibody (anti-goat and anti-rat,
1:3,000; Jackson Immuno Research, Suffolk, UK), (anti-mouse, 1:3,000,
Sigma–Aldrich, St. Louis, MO, USA). The immunoreaction was detected
using the ECL substrate (ThermoFisher Scientiﬁc, Waltham, MA, USA).
Immunohistochemistry
The animals were deeply anesthetized and transcardially perfused
using saline followed by 4% PFA. The brains were removed, post-ﬁxed
in 4% PFA for 48 h and cryopreserved with graded sucrose (10–20–
30%) over 72 h. The 30-μm parasagittal mouse brain sections were cut
using a cryostat at −20 °C, collected on silanized glass slides and
dried in a microwave oven for 4 min. The sections were stored at
−80 °C or processed immediately. The HIER procedure was applied
by boiling the sections in citrate buffer (pH 6.0) for 30min, and the sec-
tions were subsequently reduced in 1% borohydrite for 1 h. The sections
were blocked via incubation in 2% normal goat serum in PBS for 30min.
For immunoﬂuorescence staining, the sections were incubated over-
night at 4 °C with the following primary mouse antibodies: anti-
Calbindin D-28 k (1:500; Sigma–Aldrich), anti-GFAP (1:1,000; BD
Pharmingen), anti-polyQ (1:500; Millipore) and anti-ataxin-3 (1:500;
Millipore). To detect inclusions and to differentiate them from back-
ground lipofuscin aggregates, we used secondary antibodies labeled
with a hybrid ﬂuorophore that was excitable in far red (650 nm), exhib-
ited a very long Stokes shift and emitted in infrared (750 nm) (FRET
effect). The respective Alexa Fluor 750-Allophycocyanin (Invitrogen),Cy-3, Cy2, anti-rabbit and anti-mouse ﬂuorescent secondary antibodies
(Jackson ImmunoResearch; Suffolk, UK)were used at a concentration of
1:500 for 2 h at RT in PBS-Tween 20. Fluorescent confocal images were
acquired using the TCS SP5 II (Leica Microsystems; Poland) or LSM 510
META system (Zeiss; Poznan, Poland).
Densitometry assessment of immunoﬂuorescence and Purkinje cell counts
The immunoﬂuorescent signal was assessed by reading the entire
immunoﬂuorescence intensity from 20-μm-thick confocal sections
using ﬁxed detector gain values. Micrographs of the entire cerebellar
section area were visualized using the tile scan function. Single-
channel, large micrographs representing entire cerebellar sections
were then processed by selecting the stripe of Calbindin D-28 k immu-
noreactive dendrites and Purkinje cell bodies from entire cerebellar sec-
tions from three 12-month-old knock-in mice and three respective WT
mice using the “ROI” and “mean gray value” functions of ImageJ.
The Purkinje cell numbers were estimated separately for lobule 10
and lobule 4/5 of the cerebellum. Sections used for Calbindin staining
were randomly selected from series of sections through the vermis.
Five stacks (area of 387.5 μm × 387.5 μm and approximately 10 μm
thickness) composed of 10 confocal images were randomly acquired
using a 40× objective from each investigated lobule from each mouse.
Purkinje cells were then counted from each stack of confocal images
by marking the cells with the “multi-point” tool of ImageJ to count
each cell only once. Subsequently, the length of the counted Purkinje
cell layer was estimated using the “segmented line” and “measure”
tools of ImageJ.
Cell culture
Primary glial cultures were initiated from the cerebral hemispheres
or cerebella of mouse pups, and separate glial cultures were derived
from individual animals. Tissue pieces were carefully freed of meninges
and stored in ice-cold medium. Collected tissue pieces were subse-
quently chopped, incubated for 20 min in PBS containing 0.1% trypsin
and 0.02% EDTA and transferred into HBSS with 10% FBS. The tissues
were gently dissociated with plastic pipettes and directly suspended
in DMEM/F12 supplemented with 15% FBS. Cells obtained from the ce-
rebral hemispheres or the cerebellum of one mouse pup were plated
into 100 mm poly-D-ornithine (0.1 mg/ml)-coated culture dishes in
10 ml of culture medium. The cultures were incubated at 37 °C with
5% CO2. The culture medium was replaced 24 h after plating and
every third day thereafter. All experiments were performed with glial
cultures that had been sub-plated two times. Such cultures have been
shown to be highly enriched in astrocytes (Figiel and Engele, 2000).
Rotarod analysis
The rotarod protocol was adapted from that described in reference
(Hockly et al., 2003). Mice were placed on a smooth non-slip rod
(model 47600, Ugo Basile, Italy), which accelerated from 4 to 40 rpm
over a period of 570 s. The mice were tested on 4 consecutive days, for
4 trials per day, with a rest period of 20 min between the trials. The
ﬁnal rotarod performance score for each mouse was the average from
4 consecutive days.
Parallel rod ﬂoor test
The parallel rod ﬂoor apparatus together with the ANY-maze soft-
ware (Stoelting Europe, Dublin, Ireland) was used to measure locomo-
tor activity and incoordination in the mice (Kamens et al., 2005). The
animals were placed in a 20×20 cm acrylic box with a ﬂoor made of
steel rods that were spaced by 8 mm and raised approximately 1 cm
above a base steel plate. Each time a mouse's paw slipped through the
parallel rods and touched the steel plate, an error was recorded and
187P.M. Switonski et al. / Neurobiology of Disease 73 (2015) 174–188the number of errorswas used as ameasure of incoordination. The loco-
motor activity was recorded by video camera, and the distance traveled
by each mouse was determined. One day before the data collection, the
mice were acclimatized to the apparatus for a period of 20 min. During
the testing session, exploratory parameters and the number of errors
were recorded for a 10-min period. An ataxic phenotype was assessed
as a number of paw slip errors normalized to the distance traveled dur-
ing the test.
Static rod test
The setup and protocol of the static rods test was adapted from that
of Deacon (Deacon, 2013),withmodiﬁcations. In brief, 5wooden 60-cm
long rods of 35 mm, 28 mm, 21 mm, 17 mm and 9 mm in diameter
representing varying grades of difﬁculty were ﬁxed to a dedicated
shelf 60 cm above a ﬂoor that was padded to avoid any harm to the
mice. The shelf was supplied with nesting material to encourage the
mice to go towards the shelf and intensive light was spotted on the
starting point of the rod to encourage the mice to turn around and
traverse the rod. The time until the mice turned around and the time
to traverse the rod were recorded. The mice received a maximum
score of 30 s if they failed to turn around, fell off the rod, turned upside
down on the rod or failed to traverse, or any combination of these be-
haviors in this time. The mice were subjected to one day of training
and then were tested for 3 consecutive days with a 2–3 min rest be-
tween rods.
Statistics
Two-group comparisons of gene expression data were compared
using Student's t-test. Behavioral data were subjected to the repeated
measures two-way ANOVA with age and genotype or trial day and ge-
notype as independent variables, followed by Bonferroni post-tests. P
values less than 0.05 were considered signiﬁcant.
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